Cabaletta Bio Inc (CABA)vsModerna Inc (MRNA)
CABA
Cabaletta Bio Inc
$2.73
-0.36%
HEALTHCARE · Cap: $462.86M
MRNA
Moderna Inc
$143.97
+5.38%
HEALTHCARE · Cap: $56.02B
Smart Verdict
WallStSmart Research — data-driven comparison
CABA leads profitability with a 0.0% profit margin vs -141.4%. CABA earns a higher WallStSmart Score of 28/100 (F).
CABA
Avoid28
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CABA.
Margin of Safety
+70.0%
Fair Value
$134.97
Current Price
$143.97
$9.00 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 8.5x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CABA
The strongest argument for CABA centers on Debt/Equity, Price/Book.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : CABA
The primary concerns for CABA are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
CABA profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
CABA carries more volatility with a beta of 3.26 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
CABA generates stronger free cash flow (-42M), providing more financial flexibility.
Bottom Line
CABA scores higher overall (28/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Cabaletta Bio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of T-cell therapies designed for patients with B-cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?